# A Study Comparing ARB With Radium-223 vs ARB Therapy With Placebo and the Effect Upon Survival for mCRPC Patients

> **NCT04237584** · PHASE3 · TERMINATED · sponsor: **MANA RBM** · enrollment: 23 (actual)

## Conditions studied

- Metastatic Castration-resistant Prostate Cancer

## Interventions

- **DRUG:** Enzalutamide during Lead-in Period
- **DRUG:** Lead-in Enzalutamide followed by Radium-223/Enzalutamide
- **DRUG:** Lead-in Enzalutamide followed by Placebo/Enzalutamide
- **DRUG:** Darolutamide during Lead-in Period
- **DRUG:** Lead-in Darolutamide followed by Radium-223/Darolutamide
- **DRUG:** Lead-in Darolutamide followed by Placebo/Darolutamide

## Key facts

- **NCT ID:** NCT04237584
- **Lead sponsor:** MANA RBM
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-06-30
- **Primary completion:** 2022-03-07
- **Final completion:** 2022-03-07
- **Target enrollment:** 23 (ACTUAL)
- **Why stopped:** The study was stopped due to insurmountable enrollment challenges affecting trial accrual, resulting from the rapidly evolving treatment options for advanced prostate cancer.
- **Last updated:** 2022-10-07

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04237584

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04237584, "A Study Comparing ARB With Radium-223 vs ARB Therapy With Placebo and the Effect Upon Survival for mCRPC Patients". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04237584. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*